ClinicalTrials.gg
RecruitingNCT07940881SI-B037Updated Nov 17, 2026

A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors

A Phase 1 interventional study of SI-B037 in Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors and First in Human, sponsored by SystImmune Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by SystImmune Inc. (part of Sichuan Biokin Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd. — 16 open to participants now, 28 under way, 9 of them phase 3. Carcinoma, Non-Small-Cell Lung · Sichuan Biokin Pharmaceutical Co., Ltd..

Planned enrollment
10th of 29
400 · median 95
Started
2026
with 7 others
Phase 1
10 of 29
7 open now
Primary completion
2028-11
later than 20 of 27 live
Registered
29th of 29
by date

Among the 29 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd., this one is the 10th largest by planned enrollment, is one of 8 that started in 2026, is one of 10 in phase 1, reaches primary completion later than 20 of the 27 other live ones, and was the 29th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 29 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd. are open now, in 6 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Carcinoma, Non-Small-Cell Lung by Sichuan Biokin Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

The objective of the study is to evaluate the safety and tolerability of SI-B037 in participants with locally advanced or metastatic solid tumors.

Read the detailed description

This study is an open-label, multicenter, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary efficacy of SI-B037 in participants with locally advanced or metastatic solid tumors.

03

Conditions studied

  • Locally Advanced /Metastatic Solid Tumors
  • Locally Advanced / Metastatic Solid Tumors
  • First in Human
  • Metastatic Solid Cancers
  • Non Small Cell Lung Cancer
  • NSCLC
  • Lung Cancer (Diagnosis)
  • Lung Cancer (NSCLC)
  • Lung Cancer (Non-Small Cell)
  • Lung Cancer (Locally Advanced or Metastatic)
  • Melanoma (Skin Cancer)
  • Ovarian Cancer
  • Phase 1
  • Phase 1 Clinical Trial
  • Phase 1 Portion : Non Small Cell Lung Cancer(NSCLC), Small Cell Lung Cancer(SCLC)

Keywords

  • PD-1
  • VEGF
  • first in human
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed the form voluntarily and agreed to follow the trial requirements.
  • Male or Female Age ≥18 years.
  • Has a of ≥3 months.
  • Subjects with documented locally advanced or solid tumor(s) not amenable to curative surgery or radiation and have received at least 1 line of standard therapy in the metastatic setting.
  • At least 1 based on 1.1
  • Has an performance status (ECOG PS) of 0 to 1.
  • Toxicity of previous antitumor therapy has returned to level ≤1 as defined by V6.0.
  • Has no serious cardiac dysfunction and ≥50%.
  • Has adequate organ function, before enrollment
  • Sexually active fertile participants and their partners must agree to use highly effective methods of (defined in Appendix 5 of the protocol) during the course of the study and for 4 months for men and 7 months for women after the last dose of study treatment.
  • Women of (WOCBP) must have a negative serum pregnancy test at Screening and must be nonlactating.

Exclusion criteria

Exclusion Criteria:

  • Chemotherapy, biological therapy, immunotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; radical radiotherapy, major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration; oral drugs such as capecitabine, or palliative radiotherapy within 2 weeks prior to initial administration.
  • Received systemic immunostimulatory therapy (such as IFN-α, IL-2) within 4 weeks prior to the first dose or is still within 5 half-lives of the treatment (whichever is longer).
  • Participants with history of severe heart disease, such as symptomatic congestive heart failure Grade ≥2 ( 6.0), (NYHA) Grade ≥2 heart failure at any time, history of myocardial infarction, or unstable angina pectoris within 6 months before enrollment.
  • Grade ≥ 3 toxicity related to anti-angiogenic therapy (except for fever and other toxicities that the investigator believes does not pose a safety risk to trial participants) when receiving anti-angiogenic therapy in the past.
  • Participant with active or untreated hemorrhagic CNS lesions.
  • Participants with pre-existing Grade ≥2 peripheral neuropathy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Experimental: Experimental SI-B037

    SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks

    Drug: SI-B037

Interventions

  • DrugSI-B037

    SI-B037 will be administered by intravenous (IV) infusion on Day 1 every 3 weeks

06

What researchers measure

Primary outcomes

  1. Participants with Dose-Limiting Toxicities

    A DLT is defined as any of the following: * Any TEAE of ≥ Grade 3 except those that are clearly and incontrovertibly due to disease progression or extraneous cause. * Toxicity that results in a \>14-day delay in treatment. * ANC \<500/mm³ (\<0.5×10⁹/L) lasting \>7 days * Febrile neutropenia of any grade and any duration * Platelets \<50,000-25,000 mm3 with significant bleeding or platelets \<25,000 mm3 for more than 7 days * Grade 4 thrombocytopenia lasting \>72 hours. * Death not related to disease progression or extraneous cause. * Hy's law cases. * Grade 3 or higher infusion-related reactions (IRR) except for a first occurrence of Grade 3 IRR that occurs in the absence of steroid prophylaxis and resolves within 6 hours following appropriate clinical management * AST/ALT 5-8× ULN persisting \>2 weeks, both regardless of presence of liver metastases.

    Time frame: 24 months

Secondary outcomes

  1. Participants with Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and Treatment-Emergent Adverse Events (TEAEs)

    Measuring the number of patients with serious adverse events (SAEs), Adverse Events of Special Interest (AESIs), and Treatment-Emergent Adverse Events (TEAEs)

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Nov 2028, 27 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 27 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
Aug 24, 2026
Primary completionEst.
Nov 2028
CompletionEst.
Nov 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940881
Lead sponsor
SystImmune Inc.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Aug 24, 2026
Primary completion
Nov 2028 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

SystImmune Inc
Contact
SI-B037-ST-101-general-study@systimmune.com
(425) 453-6841

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion